Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Equity Ratio (2016 - 2025)

Corcept Therapeutics' Equity Ratio history spans 10 years, with the latest figure at 0.77 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 4.23% year-over-year to 0.77; the TTM value through Dec 2025 reached 0.77, down 4.23%, while the annual FY2025 figure was 0.77, 4.23% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.77 at Corcept Therapeutics, up from 0.77 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.92 in Q1 2021 and bottomed at 0.77 in Q3 2025.
  • The 5-year median for Equity Ratio is 0.84 (2024), against an average of 0.84.
  • The largest annual shift saw Equity Ratio dropped 12.45% in 2023 before it grew 4.81% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.89 in 2021, then fell by 3.01% to 0.86 in 2022, then decreased by 5.22% to 0.82 in 2023, then decreased by 0.83% to 0.81 in 2024, then fell by 4.23% to 0.77 in 2025.
  • Per Business Quant, the three most recent readings for CORT's Equity Ratio are 0.77 (Q4 2025), 0.77 (Q3 2025), and 0.79 (Q2 2025).